Gyon Technologies Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Gyon Technologies Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,882	Closed	-$646K	–	506
2021 Q4	$646K	Buy	+18,882	New	+$597K	0.12%	237
2021 Q3	–	Sell	-35,056	Closed	-$1.57M	–	467
2021 Q2	$1.57M	Buy	+35,056	New	+$1.16M	0.52%	67
2021 Q1	–	Sell	-74,652	Closed	-$1.5M	–	488
2020 Q4	$1.5M	Buy	+74,652	New	+$1.61M	0.52%	48

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Gyon Technologies Capital Management's PTGX Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 18,882 shares — an estimated $646K sold.

Gyon Technologies Capital Management first reported a position in PTGX in Q4 2020 and held it in 3 quarters. The position peaked at $1.57M in Q2 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

Gyon Technologies Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 18,882 Protagonist Therapeutics shares in Q1 2022, an estimated $646K.
Gyon Technologies Capital Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 3 quarters.
Gyon Technologies Capital Management's Protagonist Therapeutics position peaked at $1.57M in Q2 2021.
140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.